Evogene (EVGN) Receivables - Net (2012 - 2025)
Evogene (EVGN) posted Receivables - Net of $317000.0 for Q4 2025, down 16.36% sequentially from $379000.0 in Q3 2025, and down 70.94% YoY from $1.1 million in Q4 2024.
Evogene (EVGN) Receivables - Net (2012 - 2025) Analysis & Trends
Evogene has reported Receivables - Net for 14 years, with the latest figure at $317000.0 in Q4 2025.
- Quarterly Receivables - Net fell 70.94% year-over-year to $317000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $317000.0 (down 70.94% YoY) and the FY2025 annual result came in at $317000.0, down 70.94% from the prior year.
- Receivables - Net slipped to $317000.0 in Q4 2025 per EVGN's latest filing, from $379000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $2.6 million in Q1 2025 and troughed at $111000.0 in Q2 2022.
- A 5-year average of $605400.0 and a median of $352500.0 in 2022 frame the typical range for Receivables - Net.
- The widest YoY moves for Receivables - Net: up 389.8% in 2025, down 76.16% in 2025.
- Over 5 years, Receivables - Net stood at $281000.0 in 2021, then increased by 23.84% to $348000.0 in 2022, then gained by 2.59% to $357000.0 in 2023, then jumped by 205.6% to $1.1 million in 2024, then plunged by 70.94% to $317000.0 in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $317000.0, $379000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 317,000.00 |
| Dec 31, 2025 | 317,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 376,000.00 |
| Jun 30, 2024 | 376,000.00 |
| Mar 31, 2024 | 539,000.00 |
| Mar 31, 2024 | 539,000.00 |
| Dec 31, 2023 | 357,000.00 |
| Dec 31, 2023 | 357,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |